Decision Support Systems in Prostate Cancer Treatment: An Overview

Table 2

Overview of treatment support systems.

Study	N	Decision	Inputs	Outcomes	TRIPOD
(Hodges et al. 2012)[43]	Model	SBRT, IMRT	Utility, transitions	QALY, Costs, ICER	80%
(Reed et al. 2014)[44]	Model	ART	Risk group; ProsVue slope	QALY, Cost, ICER	80%
(Vanneste et al. 2015)[45]	Model	IMRT+IRS, IMRT	Utility, transitions	QALY, Cost, ICER	81%
(Smith et al. 2016)[46]	Model	RT plan	DVH, Clinical	TCP, NTCP, QALY	87%
(van Wijk et al. 2018)[47]	23	IRS in RT	DVH, Clinical	TCP, NTCP	84%
(Salem et al. 2018)[48]	200	Follow-up	Symptoms, Blood tests	Follow-up suggestion	71%
(Walsh et al. 2018)[49]	25	IMRT, V-mat, PSPT, IMPT	DVH	TCP, NTCP, Robustness, stability	84%

Abbreviations. N: number of patients; IMRT: intensity modulated radiotherapy; V-mat: volumetric-modulated arc therapy; PSPT: passively scattered proton therapy; IMPT: image modulated proton therapy; TCP: tumor control probability; NTCP: normal tissue complication probability; DVH: dose-volume histogram; QALY: quality adjusted life year; IRS: implantable rectum spacer; ART: adjuvant radiotherapy; ICER: incremental cost-effectiveness ratio; TRIPOD: adherence to the TRIPOD statement.
Clinical parameters.